Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trial.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
02 09 2023
02 09 2023
Historique:
received:
02
05
2023
accepted:
11
08
2023
medline:
4
9
2023
pubmed:
2
9
2023
entrez:
1
9
2023
Statut:
epublish
Résumé
Stereotactic ablative radiotherapy (SABR) is a standard-of-care for medically-inoperable-early-stage non-small cell lung cancer (NSCLC). One third of patients progress and chemotherapy is rarely used in this population. We questioned if addition of the immune-checkpoint-inhibitor (ICI) atezolizumab to standard-of-care SABR can improve outcomes. We initiated a multi-institutional single-arm phase I study (NCT02599454) enrolling twenty patients with the primary endpoint of maximum tolerated dose (MTD); secondary endpoints of safety and efficacy; and exploratory mechanistic correlatives. Treatment is well tolerated and full dose atezolizumab (1200 mg) is the MTD. Efficacy signals include early responses (after 2 cycles of ICI, before initiation of SABR) in 17% of patients. Biomarkers of functional adaptive immunity, including T cell activation in the tumor and response to ex-vivo stimulation by circulating T cells, are highly predictive of benefit. These results require validation and are being tested in a phase III randomized trial.
Identifiants
pubmed: 37658083
doi: 10.1038/s41467-023-40813-w
pii: 10.1038/s41467-023-40813-w
pmc: PMC10474145
doi:
Substances chimiques
atezolizumab
52CMI0WC3Y
Types de publication
Multicenter Study
Clinical Trial, Phase I
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
5332Informations de copyright
© 2023. Springer Nature Limited.
Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Clin Oncol. 2019 Feb 1;37(4):318-327
pubmed: 30557521
N Engl J Med. 2019 Mar 7;380(10):990
pubmed: 30855761
Adv Exp Med Biol. 2020;1224:53-62
pubmed: 32036604
JCO Precis Oncol. 2019;3:
pubmed: 31832578
Nature. 2014 Nov 27;515(7528):563-7
pubmed: 25428504
Int J Radiat Oncol Biol Phys. 2019 Apr 1;103(5):1077-1084
pubmed: 30513377
JAMA. 2010 Mar 17;303(11):1070-6
pubmed: 20233825
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):559-65
pubmed: 17255278
N Engl J Med. 2004 Jan 22;350(4):351-60
pubmed: 14736927
Proc Natl Acad Sci U S A. 2017 May 9;114(19):4993-4998
pubmed: 28446615
Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):1064-70
pubmed: 24210082
N Engl J Med. 2005 Jun 23;352(25):2589-97
pubmed: 15972865
J Thorac Oncol. 2018 Apr;13(4):521-532
pubmed: 29269008
Discov Med. 2021 Jan-Feb;31(162):15-20
pubmed: 34965367
Oncoimmunology. 2015 Apr 1;4(7):e1016709
pubmed: 26140246
Int J Mol Sci. 2021 Aug 30;22(17):
pubmed: 34502325
J Thorac Oncol. 2011 Sep;6(9):1496-504
pubmed: 21642859
J Clin Oncol. 2009 Jul 10;27(20):3290-6
pubmed: 19414667
Clin Cancer Res. 2019 Aug 1;25(15):4663-4673
pubmed: 31053602
Genome Biol. 2014;15(12):550
pubmed: 25516281
Radiother Oncol. 2012 Jul;104(1):62-6
pubmed: 22682749
Lancet. 2021 Oct 9;398(10308):1344-1357
pubmed: 34555333
Cancer. 2017 Feb 15;123(4):688-696
pubmed: 27741355
Lancet Oncol. 2021 Jun;22(6):824-835
pubmed: 34015311
Nat Cancer. 2021 Sep;2(9):919-931
pubmed: 34917944
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
J Mammary Gland Biol Neoplasia. 2020 Dec;25(4):417-432
pubmed: 33590360
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
Nat Commun. 2018 Aug 10;9(1):3196
pubmed: 30097571
Bioinformatics. 2005 Oct 15;21(20):3940-1
pubmed: 16096348
N Engl J Med. 2018 Dec 13;379(24):2342-2350
pubmed: 30280658
Radiother Oncol. 2010 Jan;94(1):1-11
pubmed: 20074823
PLoS One. 2016 Jun 09;11(6):e0157164
pubmed: 27281029
Clin Cancer Res. 2021 May 1;27(9):2470-2480
pubmed: 33568343
Int J Radiat Oncol Biol Phys. 2020 Sep 1;108(1):212-224
pubmed: 32417411
Lung Cancer. 2019 Apr;130:162-168
pubmed: 30885339
Lancet Oncol. 2019 Jul;20(7):924-937
pubmed: 31122901
Lancet Oncol. 2017 Jul;18(7):895-903
pubmed: 28551359
JAMA Oncol. 2019 Sep 01;5(9):1276-1282
pubmed: 31294749
Eur J Cancer. 2019 Jan;107:124-132
pubmed: 30562710
N Engl J Med. 2022 May 26;386(21):1973-1985
pubmed: 35403841
Lancet Oncol. 2006 Sep;7(9):719-27
pubmed: 16945766